人乳头状瘤病毒检测在中晚期宫颈癌患者同步放-化疗疗效评估中的意义

Role of human papillomavirus detection in evaluating outcome in locally advanced cervical cancer patients undergoing concurrent chemoradiotherapy

目的探讨人乳头状瘤病毒(HPV)检测在中晚期宫颈癌患者同步放-化疗疗效评估中的意义。方法同步行体外、腔内照射和顺铂化疗的中晚期宫颈癌患者86例,治疗前及治疗后6个月时取宫颈管分泌物以核酸分子快速杂交法检测13种HPV基因型的HPV DNA变化,评估疗效。结果 84例完成随访6个月以上,HPV DNA总阳性率19.05%,高危型HPV DNA阳性率16.67%,均明显低于治疗前的94.19%和89.53%(P<0.05)。治疗后6个月时疗效评定治疗总有效率为80.95%。结论在中晚期宫颈癌同步放-化疗期间,检测HPV感染的变化有助于疗效评估。

Objective To explore the role of human papillomavirus （HPV） detection in evaluating outcome in locally advanced cervical cancer patients undergoing concurrent chemoradiotherapy. Methods The concurrent chemoradiotherapy was performed in 86 patients undergoing concurrent chemoradiotherapy with cisplatin and irradiation in vitro and intracavity. The detection of 13 HPV genotypes and evaluation of the efficacy were carried Out before and 6 months after treatment. Results A total of 84 patients was followed-up for 6 months or more, which concluded that the overall positive rate of HPV DNA and the positive rate for high-risk type HPV DNA were lower after treatment than those before（19.05% vs. 94.19% and 16.67% vs. 89.53%） （P〈0. 05）. The effectiveness rate was 80. 95% on the 6th month after treatment. Conclusion During chemoradiation therapy in the patients with locally advanced cervical cancer, detection of the changes of HPV infection facilitates the evaluation of therapeutic outcomes.